blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP4216952

EP4216952 - TREATMENT OF COGNITIVE DYSFUNCTION WITH PYRROLOPYRIDINE-ANILINE COMPOUNDS [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  30.06.2023
Database last updated on 13.07.2024
FormerThe international publication has been made
Status updated on  02.04.2022
Most recent event   Tooltip01.12.2023Change: Validation statespublished on 03.01.2024  [2024/01]
01.12.2023Change - extension statespublished on 03.01.2024  [2024/01]
Applicant(s)For all designated states
NFlection Therapeutics, Inc.
867 Boylston Street, 5th Floor, 1116
Boston, Massachusetts 02116 / US
[2023/31]
Inventor(s)01 / POWALA, Christopher
Wayne, Pennsylvania 19087 / US
02 / PLOTKIN, Scott
Wayne, Pennsylvania 19087 / US
03 / SARIN, Kavita
Wayne, Pennsylvania 19087 / US
04 / MOREFIELD, Elaine
Wayne, Pennsylvania 19087 / US
05 / SHAHRYARI, Jahanbanoo
Wayne, Pennsylvania 19087 / US
06 / FENN, Peter
Wayne, Pennsylvania 19087 / US
 [2023/31]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[2023/31]
Application number, filing date21873410.123.09.2021
[2023/31]
WO2021US51710
Priority number, dateUS202063082595P24.09.2020         Original published format: US 202063082595 P
[2023/31]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2022066875
Date:31.03.2022
Language:EN
[2022/13]
Type: A1 Application with search report 
No.:EP4216952
Date:02.08.2023
Language:EN
The application published by WIPO in one of the EPO official languages on 31.03.2022 takes the place of the publication of the European patent application.
[2023/31]
Search report(s)International search report - published on:US31.03.2022
ClassificationIPC:A61K31/437, C07D471/04, A61P35/00
[2023/31]
CPC:
A61K9/0043 (EP,IL,US); A61K31/437 (EP,IL,US); A61K9/0073 (EP,IL,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/31]
TitleGerman:BEHANDLUNG VON KOGNITIVEN STÖRUNGEN MIT PYRROLOPYRIDINANILINVERBINDUNGEN[2023/31]
English:TREATMENT OF COGNITIVE DYSFUNCTION WITH PYRROLOPYRIDINE-ANILINE COMPOUNDS[2023/31]
French:TRAITEMENT D'UN DYSFUNCTIONNEMENT COGNITIF AVEC DES COMPOSÉS PYRROLOPYRIDINE-ANILINE[2023/31]
Entry into regional phase20.04.2023National basic fee paid 
20.04.2023Search fee paid 
20.04.2023Designation fee(s) paid 
20.04.2023Examination fee paid 
Examination procedure20.04.2023Examination requested  [2023/31]
07.11.2023Amendment by applicant (claims and/or description)
Fees paidRenewal fee
20.04.2023Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[A]WO2014210538  (UNIV CALIFORNIA [US]) [A] 1-7 * ; entire document *;
 [A]WO2018213810  (NFLECTION THERAPEUTICS INC [US]) [A] 1-7 * para [0067] *;
 [A]US2019270734  (GASSER RODOLFO [CH], et al) [A] 1-7 * ; para [0025], [0386] *;
 [A]WO2020101878  (UNIV JOHNS HOPKINS [US]) [A] 1-7* ; entire document *;
 [A]  - Klesse Laura J., Jordan Justin T., Radtke Heather B., Rosser Tena, Schorry Elizabeth, Ullrich Nicole, Viskochil David, Knight Pamela, Plotkin Scott R., Yohay Kaleb, "The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities", THE ONCOLOGIST, (20200701), vol. 25, no. 7, doi:10.1634/theoncologist.2020-0069, ISSN 1083-7159, pages e1109 - e1116, XP055928768 [A] 1-7 * ; pg. e1109, abstract, left col, Introduction: para 1 . *

DOI:   http://dx.doi.org/10.1634/theoncologist.2020-0069
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.